Replies to post #185661 on Biotech Values

[DFRAI]

HALO - update

Much of the data published for study 202 who enrolled aprox 140 patients (prior to FDA halt) - results were very good such that they are talking about a FDA meeting for first quarter to initiate a phase III registration trial. Some have mentioned applying for breakthru status. This will be a global registration trial and they estimate expenditures at 125-145MM....not sure if this covers the expense of the whole trial.

Some of the data/posters will be release in January and some at a conference in April.

They will have the option of selling rights or partnering this out if they want to.

Very positive guidance on revenues/royalties of 85-100 million, possible Enhanze partnerships as the platform has been validated by Roche and Pfizer and recently Janssen signed up.

The surprise will be Hyqvia being marketed by Baxter - how well the ramp up is since it launched in November 2014.

There is a HALO board on invhub with more info

[DewDiligence]

HALO—Brad Loncar’s (mildly bullish) 5-minute video (corrected link):

I understand (from your prior post) that you're not overly impressed with Brad's analysis, but I thought I'd post this anyhow.

[DewDiligence]

HALO—Interim update on phase-2 ‘202’ trial in pancreatic cancer from Fred Hutchinson newsletter:
http://www.fredhutch.org/en/news/center-news/2015/05/enzyme-doubles-survival-in-pancreas-cancer-patients.html

HALO’s own PR:
http://finance.yahoo.com/news/halozyme-phase-2-clinical-study-151500758.html

[DewDiligence]

(HALO)—BXLT CEO at GS webcast says HyQvia is “on track” for $1B in worldwide sales in 2020, acknowledging that the HyQvia price premium relative to ordinary IVIG won't play well in some countries. (3Q15 HyQvia sales were about $100M.)